ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
59,243.84
1.73%
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs Yen
153.445
-1.46%
Brent Oil
83.63
0.11%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) ニュース

ATNM

Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:AMEX:ATNM
日付受信時刻ニュースソース見出しコード企業名
2024/04/1821 : 00PR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
2024/04/0121 : 00PR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
2024/03/2620 : 18PR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
2024/03/1120 : 30PR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/2621 : 30PR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/2321 : 30PR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/1006 : 30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
2024/02/0614 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/0307 : 03Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
2024/01/0221 : 30PR Newswire (US)Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®AMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/1122 : 15PR Newswire (US)Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/1121 : 45PR Newswire (US)Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/0822 : 00PR Newswire (US)Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/0207 : 00Edgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/1007 : 09Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/1007 : 05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0621 : 30PR Newswire (US)Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0305 : 15PR Newswire (US)Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023AMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0222 : 05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0222 : 05PR Newswire (US)Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
2023/10/0420 : 30PR Newswire (US)Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
2023/09/2722 : 05PR Newswire (US)Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
2023/09/0721 : 40PR Newswire (US)Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOAMEX:ATNMActinium Pharmaceuticals Inc
2023/08/3120 : 00PR Newswire (US)Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
2023/08/2120 : 00PR Newswire (US)Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressAMEX:ATNMActinium Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:ATNM

最近閲覧した銘柄

CCOM
US500
US 500
NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
USOTC
BASFY
BASF (QX)
CCOM
SILVER
SILVER
NYSE
AXP
American Express
NASDAQ
AAPL
Apple
FX
USDJPY
US Dollar vs Yen
PM
XAUUSD
Gold vs US Dollar
CCOM
US100
US Tech 100
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有